FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections

Approved as Recarbrio a combination of imipenem, cilastatin and relebactam.

An antibacterial drug product to treat adults with complicated urinary tract infections and complicated intra-abdominal infections.

Cilastatin limits the renal metabolism of imipenem.

Relebactam, is a beta-lactamase inhibitor.

The drug is reserved for situations where there are limited or no alternative antibacterial drugs for treating a patient’s infection.

Using complicated urinary tract or intra-abdominal infections associated with clinical response rate of 94-99%.

Most common adverse reactions included: nausea, diarrhea, headache, fever and increased liver enzymes.

Use in patients taking ganciclovir may cause generalized seizures, and use should be avoided when taking valproic acid or divalproex sodium, drugs used to manage seizures, as a reduction in levels may lead to seizures.

Leave a Reply

Your email address will not be published. Required fields are marked *